HTDS evaluates business proposal ahead of dividend distribution

Jan 23 2010

Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) subsidiary Slavica Bio Chem recently announced entry into the stem cell bank development. An unsolicited business proposal is currently being evaluated by the company from an obstetrician type medical company. This company is engaged in a treatment for pre-term labor and induction of labor. These symptoms affect millions of people worldwide.

HTDS management hopes to build its own stem cell bank and laboratories in Serbia under supervision of its Slavica Biochem medical team and has attracted many inquiries from medical companies. As the issuer has no desire to subscribe to the Pink Sheets filing service a business plan is currently being drafted by the company medical team and will be posted on the company web site in due time.

With these bold projects well underway, HTDS management see great potential in what the other side brings to the table. A source close to the company said, "This medical company from a prosperous Middle Eastern region patented two enzymatic molecules for treatment of labor-related complications. Our understanding is one of the company's patents is pending. The company seeks cooperation with HTDS to co-develop this enzyme and meet GMP and FDA enzyme/cytokines production; as well as to develop Phase II clinical trials in China and share production and marketing with HTDS. Just to put this in perspective, Preterm or premature labor is defined as labor prior to the 37th week of gestation. Preterm birth, a complication that affects 11 percent of births in the U.S.A each year, is responsible for 75% of infant deaths and 50% of the long-term neurological handicaps, including cerebral palsy, blindness, deafness, and developmental defects. The direct cost of care in Neonatal Intensive Care Units (NICU) is a staggering $45 billion to $65 billion in the Western world, treating an estimated 1.5 million preterm babies, and totalling about 4.5 million NICU hospitalization weeks.

"The candidate doesn't wish to share any detailed information at this stage of negotiations. HTDS management is offering this general overview of the business under consideration."

The company brings attention to its filings on Pink Sheets of November 24 2009>